The dynamics of plasma transforming growth factor beta 1 (TGF-β1) level during radiotherapy with or without simultaneous chemotherapy in advanced head and neck cancer

Feltl, David; Závadová, Eva; Pála, Miloslav; Hozák, Pavel

doi:10.1016/j.oraloncology.2004.09.005

Cited by 10 publications

(6 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conversely, serum levels of TGF-β decrease significantly after curative surgical resection of colorectal tumors (41). Finally, in advanced head and neck cancers treated with chemoradiotherapy and in non-small-cell lung cancers treated with chemotherapy, a decrease in circulating TGF-β levels has been shown to correlate with response to treatment (42,43).…”

Section: Figurementioning

confidence: 99%

Inhibition of TGF-β with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression

Biswas¹,

Guix²,

Rinehart³

et al. 2007

J. Clin. Invest.

315

198

View full text Add to dashboard Cite

We investigated whether TGF-β induced by anticancer therapies accelerates tumor progression. Using the MMTV/PyVmT transgenic model of metastatic breast cancer, we show that administration of ionizing radiation or doxorubicin caused increased circulating levels of TGF-β1 as well as increased circulating tumor cells and lung metastases. These effects were abrogated by administration of a neutralizing pan-TGF-β antibody. Circulating polyomavirus middle T antigen-expressing tumor cells did not grow ex vivo in the presence of the TGF-β antibody, suggesting autocrine TGF-β is a survival signal in these cells. Radiation failed to enhance lung metastases in mice bearing tumors that lack the type II TGF-β receptor, suggesting that the increase in metastases was due, at least in part, to a direct effect of TGF-β on the cancer cells. These data implicate TGF-β induced by anticancer therapy as a prometastatic signal in tumor cells and provide a rationale for the simultaneous use of these therapies in combination with TGF-β inhibitors.

show abstract

Section: Figurementioning

confidence: 99%

Inhibition of TGF-β with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression

Biswas¹,

Guix²,

Rinehart³

et al. 2007

J. Clin. Invest.

315

198

View full text Add to dashboard Cite

show abstract

“…That is a far higher value than has been reported by others for total TGF-b1, and the assay they used may have measured factors other than TGF-b1. Generally, circulating levels of total TGF-b1 have been reported to be between 5 and 30 ng/mL [14][15][16][17]. Less than 1% of total TGF-b1 circulates as the active form [17].…”

Section: Discussionmentioning

confidence: 99%

Transforming Growth Factor β1 release by human adipose tissue is enhanced in obesity

2005

View full text Add to dashboard Cite

“…Therefore, we can look for molecules sensitive to EGFR direct treatment to indirectly inhibit the activation of this pathway and improve the efficacy of radiotherapy. The TGF-β superfamily participates in epithelial-mesenchymal transition and maintains the stem cell part, which in turn plays an important role in resistance to radiation and chemoresistance [166,167]. The study by Dorival et al emphasized that the level of TGF-β3 protein in extracellular vesicles released from HNSCC cells is a strong predictor of response to chemoradiation therapy [168].…”

Section: The Role Of Evs In the Resistance Of Hnscc To Radiotherapy Amentioning

confidence: 99%

The roles of extracellular vesicles in the development, microenvironment, anticancer drug resistance, and therapy of head and neck squamous cell carcinoma

Guo

et al. 2021

J Exp Clin Cancer Res

View full text Add to dashboard Cite

Head and neck squamous cell carcinoma (HNSCC) is one of the main malignant tumours affecting human health, mainly due to delayed diagnosis and high invasiveness. Extracellular vehicles (EVs) are membranous vesicles released by cells into the extracellular matrix that carry important signalling molecules and stably and widely exist in various body fluids, such as plasma, saliva, cerebrospinal fluid, breast milk, urine, semen, lymphatic fluid, synovial fluid, amniotic fluid, and sputum. EVs transport almost all types of bioactive molecules (DNA, mRNAs, microRNAs (miRNAs), proteins, metabolites, and even pharmacological compounds). These “cargoes” can act on recipient cells, reshaping the surrounding microenvironment and altering distant targets, ultimately affecting their biological behaviour. The extensive exploration of EVs has deepened our comprehensive understanding of HNSCC biology. In this review, we not only summarized the effect of HNSCC-derived EVs on the tumour microenvironment but also described the role of microenvironment-derived EVs in HNSCC and discussed how the “mutual dialogue” between the tumour and microenvironment mediates the growth, metastasis, angiogenesis, immune escape, and drug resistance of tumours. Finally, the clinical application of EVS in HNSCC was assessed.

show abstract

The dynamics of plasma transforming growth factor beta 1 (TGF-β1) level during radiotherapy with or without simultaneous chemotherapy in advanced head and neck cancer

Cited by 10 publications

References 22 publications

Inhibition of TGF-β with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression

Inhibition of TGF-β with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression

Transforming Growth Factor β1 release by human adipose tissue is enhanced in obesity

The roles of extracellular vesicles in the development, microenvironment, anticancer drug resistance, and therapy of head and neck squamous cell carcinoma

Contact Info

Product

Resources

About